- 2021 Examination and Enforcement Priorities for Asset Managers (April 13, 2021)
- Navigating Life Sciences M&A Under the Biden Administration | Drug Pricing & Antitrust Considerations (March 25, 2021)
- Outlook 2021 – Washington, D.C. Updates and Insights on Life Sciences and Health Care (February 25, 2021)